Hemorrhagic disease of newborn by combined blood clotting factor deficiencies is very rare. Combined deficiency of factor V and factor VIII is the most common form among these cases, and inherited by autosomal recessive trait. Clinical findings are easy bruising, post-traumatic bleeding and bleeding after tooth extractions, and the main laboratory findings are prolonged partial thromboplastin time (PTT) and prothrombin time (PT) that are different from hemophilia A only with prolonged PTT. We experienced a case of combined congenital deficiency of factor V and factor VIII in a 1-day-old boy. We report the case with brief review of literature.
Blood Coagulation ; Factor V Deficiency ; Factor V* ; Factor VIII* ; Hemophilia A ; Hemorrhage ; Humans ; Male ; Partial Thromboplastin Time ; Prothrombin Time ; Tooth Extraction ; Vitamin K Deficiency Bleeding

BACKGROUND AND OBJECTIVES: The leukotriene (LT) receptor antagonist is subject to an on-going study of allergic rhinitis, nasal polyposis and chronic paranasal sinusitis. This study was designed to evaluate the change of nasal patency and morphological changes by assessing the role of 4-oxo-8-benzopyren-hemihydrate (ONO-1078, BH), a cysLT1 receptor antagonist to treatment of allergic rhinitis. MATERIALS AND METHOD: Sixty-five guinea pigs (GPs) were divided into 3 groups: 15 for the control group, 25 for sensitized GPs group and 25 for nonsensitized GPs group. Sensitized GPs were actively sensitized by intraperitoneal injection of 10 mug DNP-As containing 1 mL Al (OH)3 and booster injections were given intraperitoneally 2, 4 and 6 weeks after the initial immunization. Measurements of nasal volume were made by acoustic rhinometry. Also transmission electron microscopy was performed to investigate ultrastructural changes of the nasal mucosal membrane in the LTD4 administrated GPs and the BH treated GPs. RESULTS: Acoustic rhinometry revealed that the changes of nasal volume showed significant reduction at 30 minutes and 6 hours after instillation of LTD4 in nonsensitized guinea pigs (GPs). However, neither nonsensitized nor sensitized GPs with systemic administration of BH showed any changes in nasal patency. Many neutrophils and eosinophils were seen in perivascular space after local administration of LTD4 in control GPs. However there are no eosinophil infiltration into the subepithelial space in BH treated GPs in both nonsensitized and sensitized group. CONCLUSION: The results suggest that BH might be a potent LT receptor antagonist in the allergic model of GPs, which reduces nasal blockage and block chemotaxis of eosinophils to the mucous membrane of the nose.
Animals ; Chemotaxis ; Eosinophils ; Guinea Pigs* ; Guinea* ; Immunization ; Injections, Intraperitoneal ; Leukotriene Antagonists ; Leukotriene D4 ; Membranes ; Microscopy, Electron, Transmission ; Mucous Membrane* ; Nasal Obstruction ; Neutrophils ; Nose ; Receptors, Leukotriene* ; Rhinitis ; Rhinometry, Acoustic ; Sinusitis

BACKGROUND: Since the bioavailability of itraconazole capsule is influenced by patients gastric acidity, it results in treatment failure due to its low dissolution and subsequent low absorption when administered in fasting. Itraconazole Melt-Extrusion tablet has been lately developed in order to improve its dissolution profile. It is the first clinical study to evaluate the efficacy and safety of itraconazole Melt-Extrusion tablet in Korea. OBJECTIVE: This study was conducted to evaluate the efficacy and safety of itraconazole melt-extrusion tablet 400mg daily for 1 week(pulse therapy) for hyperkeratotic type of tinea pedis and manus. METHODS: A clinical and mycological investigation was made of 812 outpatients with hyperkeratotic type of tinea pedis and/or tinea manus who had visited at 52 general hospitals under the lead of the Korean Dermatological Association from June to December, 1998. Patients confirmed by clinically and microscopically as hyperkeratotic type of tinea pedis and/or tinea manus were administered 2 tablets twice a day for one week and followed up for 8 weeks from the start of the medication. RESULTS: The results were summarized as follows; 1. Clinical symptoms of hyperkeratotic type of tinea pedis and/or tinea mauns were significantly improved at the end of study, week 8(p<0.001). 2. Clinical response rate, defined as more than 50% decrease of the sum of the clinical symptom scores, was 79.3%(512/646). 3. Mycological cure rate, dafined as both culture and KOH negative at week 8, was 78.2%(244 /312). 4. 40(5.5%) patients, of the 727 patients evaluable for drug safety evaluation, were reported to have adverse event. CONCLUSION: Itraconazole Melt-Extrusion tablet 400mg/day for 1 week (pulse therapy) is effective and safe in the treatment of hyperkeratotic type of tinea pedis and/or tinea manus.
Absorption ; Biological Availability ; Fasting ; Gastric Acid ; Hospitals, General ; Humans ; Itraconazole* ; Korea ; Outpatients ; Tablets ; Tinea Pedis* ; Tinea* ; Treatment Failure